Ascletis Pharma Inc. kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$16.42
Açılış fiyatı
$16.49
Günün Aralığı
$15.8 - $16.8
52 haftalık aralık
$3.92 - $18.75
İşlem hacmi
2.2M
Ort.Hacim
5.2M
EPS (TTM)
-0.30
Dividend yield
--
Piyasa Değeri
$16.3B
ASCLETIS-B nedir?
Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang and currently employs 208 full-time employees. The company went IPO on 2018-08-01. The firm focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The firm's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The firm conducts its business in the domestic and overseas markets.